Keros Therapeutics, Inc.
KROS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $560 | $331 | $279 | $230 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $4 | $1 | $1 | $18 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $25 | $15 | $6 | $3 |
| Total Curr. Assets | $589 | $347 | $286 | $251 |
| Property Plant & Equip (Net) | $23 | $19 | $18 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $1 | $1 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $2 | $2 | $3 | $1 |
| Total NC Assets | $27 | $23 | $21 | $4 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $616 | $370 | $307 | $255 |
| Liabilities | – | – | – | – |
| Payables | $5 | $5 | $3 | $4 |
| Short-Term Debt | $2 | $1 | $0 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $21 | $18 | $13 | $7 |
| Total Curr. Liab. | $27 | $24 | $17 | $12 |
| LT Debt | $17 | $13 | $13 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $17 | $13 | $13 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $19 | $14 | $13 | $1 |
| Total Liabilities | $44 | $38 | $29 | $12 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$569 | -$381 | -$228 | -$124 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,140 | $714 | $506 | $367 |
| Total Equity | $572 | $332 | $277 | $243 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $616 | $370 | $307 | $255 |
| Net Debt | -$541 | -$317 | -$266 | -$229 |